UNLIMITED TURBO LONG - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 15:50:23 2024-06-21 EDT | ||
| 1.99 EUR | +11.80% |
|
| Current month | +48.51% | ||
| 1 month | +21.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 1.99 | +11.80% |
| 24-06-20 | 1.78 | +42.40% |
| 24-06-19 | 1.25 | -1.57% |
| 24-06-18 | 1.27 | -9.93% |
| 24-06-17 | 1.41 | -3.42% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 03:50 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PZ7KAT |
| ISIN | DE000PZ7KAT5 |
| Date issued | 2019-04-01 |
| Strike | 50.23 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.08 € |
|---|---|
| Lowest since issue | 0.86 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.67
USD
Average target price
82.7
USD
Spread / Average Target
+17.02%
- Stock Market
- Certificates
- Certificat
